
|Articles|November 22, 2004
Risks of COX-2 vs. NSAID?
A 60-year-old Hispanic man, L.C., is being discharged from your hospital after an episode of gastrointestinal bleeding. Prior to admission he was switched to naproxen 500 mg b.i.d. for his osteoarthritis when rofecoxib (Vioxx, Merck) was taken off the market. Dismissal orders include ongoing medications: metformin 850 mg b.i.d., pravastatin 40 mg q.d., ramipril (Altace, Aventis) 10 mg q.d., now with the addition of lansoprazole (Prevacid, TAP) 30 mg q.d. L.C.'s physician is in a quandary about whether to prescribe a different COX-2 inhibitor or an NSAID. Previously, L.C. failed to obtain pain relief from acetaminophen or salsalate therapy. What do you recommend?
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Navigating Compounding Peptides and GLP-1s Through Regulations
2
Understanding the Restructure of US Pharmacy Benefits Amid Reform, Regulatory Action
3
The 2026 GLP-1 Compounding Crackdown: A Pharmacist’s Guide
4
Pharmacist Involvement Speeds Prior Authorization for GLP-1s
5


























